Central eSource transforms the conduct of clinical trials by replacing disparate, site-specific source templates with a unified, sponsor-designed framework.

Now, more than ever, sponsors aim to empower the global patient voice through patient-centric technologies—including providing wearable technologies and using electronic clinical outcome assessments (eCOAs) to collect patient data.

Regulators prioritize patient-reported outcomes. Cognitive assessments in Phase 1 trials detect early drug-related cognitive effects, ensuring safety and efficacy. Signant’s CDR System® is a proven tool for this.

ePRO and eCOA are helping to overcome oncology-specific challenges in clinical research. Find out how you can make life easier for patients when it matters most.

No matter how conclusive clinical evidence is for medical treatments, developers may struggle to see precisely how their treatment performs in the real world—outside the controlled environment of the clinic or office.

The clinical research industry has been reluctant to adopt eConsent for several reasons. Unearth how the industry should continue exploring and implementing digital technologies in earnest in the future.

In honor of World Movement Disorders Day, we highlight advances in Parkinson’s disease care. At the 2024 MDS Congress, Signant presented research on electronic diaries for tracking PD patients' functional status.

ePRO and eCOA are helping to overcome oncology-specific challenges in clinical research. Find out how you can make life easier for patients when it matters most.

Discover how sponsors can save time and effort by applying for clinical trial authorization once across the EU using the Clinical Trials Information System (CTIS).